Quince Therapeutics, Inc. (QNCX)

Market Cap	31.70M -63.1%
Revenue (ttm)	n/a
Net Income	-36.16M
EPS	-137.27
Shares Out	977.96K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,420
Open	30.89
Previous Close	31.26
Day's Range	30.89 - 33.74
52-Week Range	15.10 - 909.98
Beta	1.26
Analysts	Buy
Price Target	82.75 (+155.32%)
Earnings Date	Aug 20, 2026

About QNCX

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a dr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 9, 2019
• Employees: 38
• Stock Exchange: NASDAQ
• Ticker Symbol: QNCX
• Website: https://quincetx.com

Analyst Summary

According to 6 analysts, the average rating for QNCX stock is "Buy." The 12-month stock price target is $82.75, which is an increase of 155.32% from the latest price.

Price Target

$82.75

(155.32% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 14, 2026

Data Sources Report a data error